FDA Approves New Combination Treatment for NSCLC

2018-11-01T20:42:17+00:00October 31st, 2018|Hot Topics, News|

Tuesday, October 30, 2018 – Today the Food and Drug Administration (FDA) approved immunotherapy drug, pembrolizumab, also known as KEYTRUDA, in combination with chemotherapies, carboplatin, and either paclitaxel or nab-paclitaxel as a first-line treatment for patients with metastatic squamous non-small cell lung cancer (NSCLC). The results of the randomized trial showed an increase in overall survival, progression-free survival and overall response rate. Click here to read the full press release.

FDA expands approval of Gilotrif (afatinib) for NSCLC

2018-03-21T20:16:59+00:00January 17th, 2018|Hot Topics, News|

Tuesday, January 16, 2018 – The FDA expanded approval of Gilotrif (afatinib), a first-line treatment for patients with non-small cell lung carcinoma (NSCLC) that is epidermal growth factor receptor (EGFR) mutation-positive. Patients with lung cancers with EGFR S768I, L861Q and G719X may now take Gilotrif. Gilotrif, an oral, once-daily EGFR-directed therapy developed by Boehringer Ingelheim, is currently approved in the U.S. to treat people with NSCLC that has certain EGFR gene changes, has spread to other parts of the body [...]

FDA Approves First-Line Treatment for NSCLC with ALK Biomarker

2018-03-23T14:58:25+00:00November 7th, 2017|Hot Topics, News|

Monday, November 6, 2017 - The United States Food and Drug Administration (FDA) approved Alecensa (alectinib) as a first treatment for advanced non-small cell lung cancer that is positive for a biomarker called ALK.  Alecensa was already approved for ALK+ lung cancer that was resistant to other ALK-targeted therapies. Now, a large randomized clinical trial showed that Alecensa was more effective than previous first-line treatment.  Patients had an average of 25.7 months without their cancer progressing (getting worse) when taking [...]

No announcement available or all announcement expired.